Company Profile
Chronicle of Events
Contact Us
New Drug R&D
Production Quality
Commercialization
Global Cooperation
R&D Pipeline
Talent Development Concept
Career Opportunities
Sunshine Guojian announced recently that Xenopax, the only humanized anti-CD25 monoclonal antibody injection approved for marketing in China, has been officially launched. The monoclonal antibody drug is independently developed by Sunshine Guojian and used for prevention of acute rejection after renal transplantation. It can be combined with the routine immunosuppression regime to significantly improve the survival rate of transplanted organs and the quality of life of patients.
SHENYANG, China, SHANGHAI, China, and WAEDENSWIL, Switzerland — December [12], 2019 — 3SBio Inc. (“3SBio”, HKEX:1530) and Numab Therapeutics (“Numab”) announced today on a collaboration agreement, pursuant to which Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
(October 17, 2019, Shanghai) The first prescription of the humanized anti-CD25 monoclonal antibody drug developed independently in China was issued in Zhongshan Hospital Affiliated to Fudan University today. The monoclonal antibody drug is independently developed by Sunshine Guojian, and is used for prevention of acute rejection after renal transplantation. Professor Zhu Tongyu, Vice President of Zhongshan Hospital Affiliated to Fudan University, said: “The first prescription of Xenopax means that Chinese transplant recipients can have access to more treatment options, and it also marks that the pharmaceutical capability in the field of immunotherapy in China has reached the international first-class level. Sunshine Guojian is expected to develop more and better biological preparations and make contribution to the improvement of China’s medical capability.”
(Shanghai, China, 29 July 2019) Today, China’s leading biopharmaceutical company Sunshine Pharmaceuticals Co., Ltd. (01530.HK) announced, the application for new drug production of the antibody fusion protein medicine YISAIPU pre-filled solution (common name: Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ: IgG Fc Fusion Protein for Injection) independently developed by its Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd has been submitted to the National Medical Products Administration and accepted.
On May 17, 2019, Sunshine Guojian’s antibody drug YISAIPU was officially granted the GMP certificate in Indonesia.
On December 16, 2018, the friendly match between Sunshine Guojian football team and Quintiles football team went on smoothly under the warm invitation of two teams. After 90 minutes of fierce competition, Sunshine Guojian football team defeated their opponents 4-2.
